01 2Dymista
02 1Flixotide
03 1Flixotide /Flovent
04 8Flixotide/Flovent
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 581
2019 Revenue in Millions : 872
Growth (%) : -33
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 601
2020 Revenue in Millions : 574
Growth (%) : 6
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 672
2021 Revenue in Millions : 601
Growth (%) : 12
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 180
2021 Revenue in Millions : 168
Growth (%) : 7
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 487
2022 Revenue in Millions : 672
Growth (%) : -17
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 200
2022 Revenue in Millions : 180
Growth (%) : 11
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2015 Revenue in Millions : 997
2014 Revenue in Millions : 885
Growth (%) : -11%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : -11.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 790
2015 Revenue in Millions : 773
Growth (%) : 2
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 840
2016 Revenue in Millions : 898
Growth (%) : -6
LOOKING FOR A SUPPLIER?